BMRN vs FLGT · P/E 40, rev $1.76B vs rev $156.5M
Biomarin Pharmaceutical Inc (BMRN) versus Fulgent Genetics Inc (FLGT) — a side-by-side from cached financials, not a winner call.
Biomarin Pharmaceutical Inc (BMRN) is a biotechnology company listed on NASDAQ.
Fulgent Genetics Inc (FLGT) is a diagnostics & research company listed on US.
Latest reported BMRN revenue for 2026-06-30 was $1.76B. Net income was $150.3M. BMRN currently screens at market cap $10.63B and trailing P/E 39.6.
Latest reported FLGT revenue for 2026-06-30 was $156.5M. Net income was -$54.4M. FLGT currently screens at market cap $586.6M.
BMRN currently screens at market cap $10.63B and trailing P/E 39.6. FLGT currently screens at market cap $586.6M.
Not investment advice. Open the BMRN and FLGT stock pages for the full models.
Not investment advice.